Asahi Kasei has appointed Ken Shinomiya as the new leader in the healthcare division following Richard Packer's tenure. Shinomiya was formerly president of Asahi Kasei Life Science, bringing rich experience and strategic vision to advance the company's healthcare portfolio. Under his leadership, Kasei aims to accelerate global growth in medicine, life sciences and critical care, further strengthening his commitment to improving patient outcomes around the world.
The new teacher's journey in the healthcare industry includes key roles, including Vice President of Strategy at Zoll Medical and Head of Bioprocessing at Asahi Kasei Medical. He became president of Asako Kasei Medical in 2023 and later became president of Asahi Kasei Life Sciences, leading the company's life science business. This includes the addition of essential services such as contract research and biology development, as well as the acquisition of Bionova Scientific in the United States.
Asahi Kasei's healthcare sector has seen major globalization, particularly since its acquisition of Zoll Medical in 2012 and established a strong presence in the US critical care market. The sector's continued global expansion is supported by target investments such as mergers and acquisitions, and strategic moves such as relocating headquarters to the US in 2023.
With Shinomiya at the helm, Asahi Kasei's healthcare sector is poised to continue its long-term growth strategy with an operating profit of ¥150 billion by 2030. “We will continue to evolve from a global perspective to promote growth around the world and enhance patient care.”
Online details
